Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus
ConclusionsCompared with DAPA + SAXA or SAXA, DAPA appears to be a cost-effective therapy as add-on to MET for Chinese patients whose T2DM is insufficiently controlled by MET.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research
More News: China Health | Dapagliflozin | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Economics | Endocrinology | Fortamet | Forxiga | Health Management | Metformin | Study | UK Health